Company Filing History:
Years Active: 2003
Title: Douglas Loftus: Innovator in Tumor Immunology
Introduction
Douglas Loftus is a notable inventor based in Silver Spring, MD (US). He has made significant contributions to the field of tumor immunology, particularly through his innovative research and patent work. His dedication to advancing therapeutic methods for treating tumor-bearing patients has positioned him as a key figure in this area of study.
Latest Patents
Douglas Loftus holds a patent for a cDNA clone for tumor rejection antigen gp110 and tumor peptide vaccine. This patent discloses an isolated cDNA molecule that comprises an amino acid sequence encoding an amino-terminal protein fragment of murine glycoprotein 110. The patent also outlines therapeutic methods for treating tumor-bearing patients, as well as prophylactic methods for vaccinating patients. Additionally, an animal model for studying tumors is disclosed in this patent. He has 1 patent to his name.
Career Highlights
Douglas Loftus is affiliated with the University of Pittsburgh, where he continues to engage in groundbreaking research. His work has been instrumental in developing new strategies for cancer treatment and prevention. His innovative approach has garnered attention in the scientific community.
Collaborations
Some of his notable coworkers include Albert B DeLeo and Ettore Appella. Their collaborative efforts have contributed to advancements in tumor immunology and vaccine development.
Conclusion
Douglas Loftus is a prominent inventor whose work in tumor immunology has the potential to impact cancer treatment significantly. His patent on the cDNA clone for tumor rejection antigen gp110 exemplifies his commitment to advancing medical science.